上班族美股台股園地

值得紀念的一天

1/28
BRKB 上漲 ($58.00) (2.0%)
G 上漲($5.75) (12.5%)
巴菲特希望湊足1億股PG,
目前而言我並不想買進G,原因很簡單,本益比31~32左右太高了,
不過我也不希望出現不到一股的PG零股,所以我會買幾股G湊整數.

有好消息也有壞消息
MRK(-$3.16) (-10.1%)





http://udn.com/NEWS/FINANCE/FIN6/2488515.shtml

寶鹼公司（P&G）28日證實，計劃以總計約570億美元的現金和股票，收購吉列公司（Gillette）.

寶鹼同意以0.975股的自家股票，換購1股吉列股票。按寶鹼27日紐約每股收盤價55.32美元計算，這樁交易相當於提供吉列股東每股約54美元的收購價碼，約比吉列27日收盤價每股45.85美元溢價18%。
一大贏家是吉列最大股東波克夏公司（Berkshire Hath-away）。波克夏董事長巴菲特說，這是一樁「夢幻交易」，「會形成世界最大的消費品公司」。巴菲特表示，計劃加碼買足吉列股票，那麼在交易完成之前，即可獲得1億股寶鹼股票。波克夏目前的吉列持股約9,600萬股，占9.67%股權，約可換得寶鹼9,360萬股。
此併購案27日已獲兩家公司的董事會通過

=====
有好消息也有壞消息

MRK(-$3.16) (-10.1%)
既Vioxx事件後,Fosamax專利比預期提早十年到期.

http://www.forbes.com/markets/2005/01/28/.......
NEW YORK - In the headlines this afternoon, more headaches for Merck. The U.S. Securities and Exchange Commission upgraded its inquiry into Merck's (nyse: MRK - news - people ) handling of Vioxx to a formal investigation. In September, Merck withdrew its blockbuster arthritis drug after a study linked it to a higher risk for heart attacks and strokes. The withdrawal sparked an uproar over drug safety, as scrutiny spread to rival Pfizer (nyse: PFE - news - people ), which sells similar drugs, and the U.S. Food and Drug Administration. To make matters worse, the pharmaceutical giant will lose U.S. patent protection on its second-biggest product, Fosamax, 10 years earlier than expected. Merck plans to appeal. A federal judge ruled Merck's patent on its $3.2 billion-per-year osteoporosis drug will expire in 2008. The ruling is a victory for Teva Pharmaceutical Industries (nasdaq: TEVA - news - people ), which challenged the patent. Teva enjoyed another victory today, saying the FDA approved its generic version of Bristol-Myers Squibb's (nyse: BMY - news - people ) Glucovance diabetes treatment.

posted by USstock @ 10:40 PM